Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - sildenafil citrate, quantity: 70.2 mg (equivalent: sildenafil, qty 50 mg) - tablet, uncoated - excipient ingredients: indigo carmine aluminium lake; croscarmellose sodium; microcrystalline cellulose; calcium hydrogen phosphate; magnesium stearate; copovidone; saccharin sodium - noumed sildenafil is indicated for the treatment of erectile dysfunction in adult males. noumed sildenafil is not indicated for use by women.

New Zealand - English - Medsafe (Medicines Safety Authority)

noumed pharmaceuticals limited - dexamfetamine sulfate 5mg;  ;   - tablet - 5 mg - active: dexamfetamine sulfate 5mg     excipient: acacia colloidal silicon dioxide lactose monohydrate magnesium stearate maize starch purified talc - the treatment of well-established and proven narcolepsy.

New Zealand - English - Medsafe (Medicines Safety Authority)

noumed pharmaceuticals limited - paracetamol 665mg - modified release tablet - 665 mg - active: paracetamol 665mg excipient: croscarmellose sodium hypromellose magnesium stearate maize starch opadry white oy-58900 povidone - effective for the relief of persistent pain associated with osteoarthritis for up to eight hours

New Zealand - English - Medsafe (Medicines Safety Authority)

noumed pharmaceuticals limited - isoniazid 100mg - tablet - 100 mg - active: isoniazid 100mg excipient: lactose monohydrate magnesium stearate purified water wheat starch as 9.50mg + 60.9mg (includes 10% overage for loss on drying) - isoniazid is indicated for the treatment of pulmonary and extrapulmonary tuberculosis in combination with other antitubercular agents.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - mirtazapine, quantity: 45 mg - tablet, film coated - excipient ingredients: hyprolose; hypromellose; magnesium stearate; lactose monohydrate; titanium dioxide; macrogol 8000; maize starch; colloidal anhydrous silica - treatment of major depression.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - mirtazapine, quantity: 30 mg - tablet, film coated - excipient ingredients: macrogol 8000; hyprolose; iron oxide yellow; colloidal anhydrous silica; iron oxide red; iron oxide black; hypromellose; magnesium stearate; titanium dioxide; maize starch; lactose monohydrate - treatment of major depression.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - fluoxetine hydrochloride, quantity: 22.4 mg (equivalent: fluoxetine, qty 20 mg) - capsule, hard - excipient ingredients: titanium dioxide; iron oxide yellow; dimeticone 350; gelatin; patent blue v; pregelatinised maize starch - treatment of major depression. treatment of obsessive compulsive disorder (ocd). treatment of major depression. treatment of obsessive compulsive disorder (ocd).

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - escitalopram oxalate, quantity: 25.54 mg (equivalent: escitalopram, qty 20 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; hypromellose; titanium dioxide; microcrystalline cellulose; macrogol 6000; purified talc; croscarmellose sodium; magnesium stearate; lactose monohydrate - treatment of major depression. treatment of obsessive compulsive disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - escitalopram oxalate, quantity: 12.77 mg (equivalent: escitalopram, qty 10 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; purified talc; hypromellose; macrogol 6000; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; lactose monohydrate; titanium dioxide - treatment of major depression. treatment of obsessive compulsive disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - azathioprine, quantity: 50 mg - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; titanium dioxide; lactose monohydrate; maize starch; purified talc; povidone; hypromellose; microcrystalline cellulose; peg-8 stearate - immunosuppressant antimetabolite: either alone, or more commonly, in combination with other agents (usually corticosteroids) and procedures which influence the immune response. therapeutic effect may be evident only after weeks or months and can include a steroid-sparing effect, thereby reducing the toxicity associated with higher dosage and prolonged usage of corticosteroids. azathioprine, in combination with cortocosteroids and/or other immunosuppressive agents and procedures, is indicated in the management of patients receiving organ transplants. azathioprine, either alone or more usually in combination with corticosteroids and/or other procedures, has been used with clinical benefit which may include reduction of dosage or discontinuation of corticosteroids, in a proportion of patients suffering from the following: severe rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis/polymyositis, autoimmune chronic active hepatitis, pemphigus vulgaris, polyarteritis nodosa, autoimmune haemolytic anaemia, chronic refractory idiopathic thrombocytopenic purpura.